These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30401502)

  • 1. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines.
    Sklepari M; Lougiakis N; Papastathopoulos A; Pouli N; Marakos P; Myrianthopoulos V; Robert T; Bach S; Mikros E; Ruchaud S
    Chem Pharm Bull (Tokyo); 2017; 65(1):66-81. PubMed ID: 28049917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
    Mariano M; Hartmann RW; Engel M
    Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A.
    Miyazaki Y; Kikuchi M; Umezawa K; Descamps A; Nakamura D; Furuie G; Sumida T; Saito K; Kimura N; Niwa T; Sumida Y; Umehara T; Hosoya T; Kii I
    Eur J Med Chem; 2022 Jan; 227():113948. PubMed ID: 34742017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
    Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes.
    Guan L; Li A; Song P; Su W; Zhang S; Chen J; Jiao X; Li W
    Bioorg Chem; 2024 Oct; 151():107676. PubMed ID: 39068716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
    Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
    Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
    Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
    Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
    Gehlot P; Pathak R; Kumar S; Choudhary NK; Vyas VK
    Bioorg Med Chem; 2024 Nov; 113():117925. PubMed ID: 39357433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
    Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
    Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
    ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of dual specificity kinase activity of DYRK1A.
    Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
    FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
    Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
    J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.